Science

Articles

• Vect-Horus appoints Dr Jamal Temsamani as Director of Drug Development & Corporate
  28 January 2019, by Jonathan NOWAK

  VECT-HORUS announced today the appointment of Dr. Jamal Temsamani as Director in charge of Drug Development & Corporate. He will lead the Company’s drug development programs from discovery to early clinical and will be in charge of industrial partnerships. Dr. Jamal Temsamani is also a member of the Management Committee of VECT-HORUS.

• Meet Vect-Horus at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit, Boston, August 21-23, 2024
  21 August 2024, by Emmanuelle BETTENDORF

  VECT-HORUS S.A.S. will be presenting a poster at the 3rd Annual Next Gen Lipid-Based Nanoparticles Delivery Summit!
  This high-profile event is taking place in Boston, MA from August 20-22, and Pavlo Shpak-Kraievskyi, Project leader, is looking forward to attending.
  Poster Title: VECTrans® Technology for CNS Targeting by Lipid Nanoparticles
  📆 Save the date: 3:30pm ET, Wednesday August 21st
  🌐 Learn More: https://ter.li/b5vw3f

• 3rd Annual RNAi-Based Therapeutics Summit from April 19th to 21th, 2022, in Boston
  12 April 2022, by Elodie DORMES

  Michel KHRESTCHATISKY, Scientific Counsel, will have a talk entitled “Development of Molecular Vectors for Targeted Delivery of RNAi” and Elodie DORMES, Sr BD Manager, will also be there and pleased to meet you in person during the summit.

• Vect-Horus will participate to the event “Espace & Santé” co-organized by CNES, Region Paca and DHUNE on March 29, 2022
  28 October 2020, by Elodie DORMES

  Michel KHRESTCHATISKY will be part of the roundtable 4 and will present the company latest results in connection with “Maintaining and increasing performance – intelligent human machine interfaces, brain tech, exoskeletons, human factor, psychology… ”
  You can access to the program by following the link: https://sante-espace.com/

• Vect-Horus strengthens its scientific advisory board with the appointment of Dr. Julia ALTERMAN
  22 March 2022, by Elodie DORMES

  Vect-Horus extends its Scientific Advisory Board with the expertise of Dr. Julia Alterman on siRNA chemical modification for extra-hepatic delivery.

• Society for the study of Blood-Brain interfaces SEISC 2019 congres
  27 November 2019, by Elodie DORMES

  Stéphane GIRARD will present iPS cell-derived model of the human blood-brain-barrier on Friday 15, Nov Session 1 of the Society for the study of Blood-Brain interfaces SEISC 2019 congres in Paris

• Meet Vect-Horus at 3rd Oligonucleotides for CNS Summit in Boston June 6-8th, 2023
  30 June 2023, by Elodie DORMES

  Meet with Michel KHRESTCHATISKY and Guillaume JACQUOT at the 3rd Oligonucleotides for CNS Summit 2023, dedicated to optimizing antisense and RNA chemistry for brain delivery, in Boston from June 6-8th, 2023.

• Vect-Horus validates the potential of its peptide vectors to transport proteins or antibodies, across the blood-brain barrier via receptor mediated transport
  28 January 2019, by Jonathan NOWAK

  (Molino et al., 2017, The FASEB Journal)
  www.fasebj.org/content/early/2017/01/19/fj.201600827R.abstract

• ECMED EU-GliaPhD international conference in MALTA
  28 January 2019, by Jonathan NOWAK

  Michel Khrestchatisky and Grigorios Kyriatzis (Early Stage Researcher, ESR), both members of the ITN Marie Curie project ECMED will participate in the ECMED EU-GliaPhD international conference organized in Malta, April 29 to May 2, 2018. Michel Khrestchatisky will give a talk on the ongoing projects of his group and biotechnology partner Vect-Horus, also member of the ECMED consortium, while Grigorios Kyriatzis presented results of his ongoing PhD project.

• Vect-Horus will participate to the “R&D Seminar IMAGING 2022” organized by the Cerimed September 26-30, 2022
  26 September 2022, by Elodie DORMES

  VECT-HORUS S.A.S. will participate in the next event dedicated to Imaging and organized by CERIMED: “R&D Seminar IMAGING 2022” from Monday, 26th September to Friday 30th September.
  Cedric MALICET will give a talk, « From bench to Clinic », Thursday, 29th September in the workshop intitled “NUCLEAR MEDICINE Imaging”.
  It will be the occasion to present Vect-Horus technology, the last imaging results generated by in vitro and in vivo TEP with our #LDLR vectors currently in clinical study (…)